Adalimumab Treats Hidradenitis Suppurativa But Has Multisystem Adverse Event Profile

Adalimumab effectively improves symptoms of hidradenitis suppurativa (HS) and quality of life in HS patients, yet causes a wide variety of adverse events that are most concerning in mental health, according to data from an analysis published in Dermatologic Therapy.

Investigators conducted a retrospective cross-sectional study to evaluate adalimumab’s effect on physical symptoms and quality of life in adult patients with moderate to severe HS who failed conventional HS treatment and were on adalimumab therapy (40 mg weekly) for at least 6 months. The HS physician global assessment (HS-PGA) was employed to assess physical symptoms and the disease life quality index (DLQI) score to assess quality of life.

Their secondary objective was to record any patient-reported adverse effects, as well as psychological, social, and occupational effects.

There were 101 patients included in the final analysis, and 23 were excluded from the HS-PGA score analysis due to inadequate reporting. Of the remaining 78 patients (77%), 62 had improved HS-PGA scores, with 24 of 62 reporting improvement in discharge, 18 of 62 reporting improved nodules, 16 of 62 reporting improved pain, and 6 of 62 reporting complete remission.

Investigators found a significant improvement in the DLQI scores recorded in patients before (n=48) and after (n=45) adalimumab treatment initiation in both paired (n=26) and unpaired data groups (P =.0001).

Of the original 101 patients started on adalimumab, 3 reported improvements in body image and ability to wear their preferred clothing, 2 reported improved joint mobility, and 3 reported improved occupational function.

There were 32 (31.7%) patients who reported adverse effects. Of note, 3 patients with a history of mental health disorders reported psychological side effects including depression, obsessive compulsive disorder (OCD) symptoms, increased preexisting anorexia nervosa symptoms, and worsening of preexisting suicidal ideation. A total of 28 (27.7%) patients stopped treatment, most (n=20) citing adverse events that spanned multiple organ systems as their reason.

Study limitations included limited data on smoking and BMI, 2 known confounding factors for HS.

“Based on our study findings, we strongly advocate for regular systemic and holistic assessment for patients with HS on long-term biologic treatment,” the study authors wrote.


Muralidharan V, Pathmarajah P, Peterknecht E, et al. Real life data on the biopsychosocial effects of adalimumab in the management of hidradenitis suppurative: A multicenter cross-sectional analysis and consideration of a multisystem monitoring approach to follow up. Dermatol Ther. Published online January 5, 2021. doi:10.1111/dth.14643

Source link

In Remembrance: Robert Joseph Baker

by Leigh Anne Maynard

I have never written an extended obit.  I have never had too. Bobby always did. Bobby always did a lot of things for me. I have worked hard in my career at The Manning Times but I do credit a lot of my success to Bobby. He was my number one fan, faithful and loyal. He was one of my best friends. 

Robert Joseph Baker worked for The Sumter Daily Item, for, to the best of my knowledge, eleven years before he came to work with me at The Manning Times. We had so much fun at the paper. We attended many events together and made many deadlines together. Some of my best adventures the last eleven years, from appearing on  The Jeffrey Lampkin Show to taking pictures for magazines along I95, were had with him. He would attend my children’s plays and games. He became part of the family. 

Bobby was sick. He had been sick for many years. When I met him eleven years ago he explained to me that he had a condition known as Hidradenitis Suppurativa. It is a painful clogging of the sweat glands that causes sores in the underarm, leg and groin areas in both men and women and additionally in the breast tissue in women. Several doctors have taken the drastic measure of removing the offending glands and infected tissues and Bobby had chosen to undergo the procedure. We talked about it and his condition often.  His strength to endure the physical pain of this condition was amazing.  

The year that we cohosted Relay together is when he found out he had Kidney failure. It was always his biggest fear.  He could not imagine being on dialysis. He was scared to go to the Kidney doctor but we knew something was wrong. I accompanied him on his first visit to Dr. Cain in Sumter and was there when he found out that his kidneys were indeed failing.  He continued to work with me and was even able to do his dialysis in his office.  He worked until it physically became impossible then he still worked a little more for me from his bed.

Bobby had a passion for writing and won many journalistic awards over his news media career. In the past few weeks he had been talking about writing a column for us again. I am sad he will not get that opportunity. His quick wit and dry sense of humor even when things seemed at their worst could still produce a smile from even the toughest critic. 

I will not sugar coat things, with Bobby you always knew where you stood. If he didn’t care for you, you knew it. But if he did he would do anything in the world for you. Although he lived in Sumter, his heart lived in Manning. He loved the community and the people. Well, most of them. Manning was his home.  When I received the phone call that my father had passed Bobby was standing right beside me in my living room, when he found his own father deceased just a few short years later I was his first call. I will miss him terribly and never thought he would be gone this young. We both have our forty year birthdays coming up this year and we were already giving each other a fit about it. I hate that he will not be able to celebrate that with me. I am still in shock that he is gone and probably will be for a while.

You can rest now Bobby.  I will miss you.

The full obituary from Stephens Funeral Home follows:

Robert “Bobby” Joseph Baker, 39, passed away Saturday, February 27, 2021, at his home.

Born April 22, 1981, in Sumter, he was the son of Marcia Christine Richardson Baker and the late Troy Lynn Baker. He worked in the news media business and he was a member of New Salem Baptist Church. 

He is survived by his mother of Sumter; two step sisters, Robin Purdy and Cindy Barrett; and two step great nieces, Whitney and Alaina.

In addition to his father, he was preceded in death by his maternal grandparents, Robert W. Richardson and Jennie Ruth Richardson. 

A memorial service was held at 2 p.m. on Wednesday, March 3, 2021, in the chapel of Stephens Funeral Home with the Rev. Dr. Kevin Massey officiating. 

Visitation was held one hour prior to the service from 1 to 2 p.m. at Stephens Funeral Home.

Memorials may be made to the National Kidney Center, 20081 Whistling Straits Place, Ashburn, VA 20147.

Stephens Funeral Home & Crematory, 304 N. Church Street, Manning, is in charge of the arrangements, (803) 435-2179.

Source link

Treatment of hidradenitis suppurativa with tetracycline, doxycycline, or lymecycline: a prospective study – Jørgensen – – International Journal of Dermatology


To evaluate the clinical efficacy of tetracycline, doxycycline, and lymecycline in patients with hidradenitis suppurativa (HS).


A prospective study of three different treatment regimens in patients with HS; oral tetracycline 500 mg twice daily, oral doxycycline 100 mg twice daily, and oral lymecycline 300 mg twice daily were administered in patients with HS. Outcomes were change in Hidradenitis Suppurativa Score (HSS), Dermatology Life Quality Life index (DLQI), overall disease‐related distress, boil‐related pain, number of boils in the preceding month, fraction of patients with no boils in the preceding month, and Physician’s Global Assessment (PGA) score at follow‐up.


In total, 108 patients, 73 (67.6%) women and 35 (32.4%) men, were included. Mean duration of treatment was 4.3 months. The mean HSS at baseline was 26.10 (SD 20.18) points, improving to 17.97 (SD 17.88) at follow‐up, difference is 8.13 (95% CI 5.21–10.93), P < 0.0001. Highest improvement in HSS was observed in the tetracycline group. After multivariate adjustment, higher reduction in HSS was significantly associated with lower BMI, Hurley stage III, higher HSS at baseline, and higher number of boils in the preceding month at baseline.


Oral treatment with tetracycline, doxycycline, and lymecycline appears effective and safe in HS patients. Tetracycline provided the greatest clinical improvement measured by HSS.

Source link

Global and Japan Hidradenitis Suppurativa Therapeutics Market 2020 In-depth Assessment, Key Trend, Industry Drivers, Future Roadmap by 2025

Cureus | Negative Pressure Wound Therapy with Instillation and Dwell Time in  the Surgical Management of Severe Hidradenitis Suppurativa

The latest research report called Global and Japan Hidradenitis Suppurativa Therapeutics Market Growth (Status and Outlook) 2020-2025 was published by to guide the business. The report includes an overview and deep study of factors where market size, market share, different dynamics of the industry, market companies, regional analysis of the domestic markets, value chain analysis, consumption, demand, key application areas have been evaluated. The report focuses on the global major leading industry players of the global and Japan Hidradenitis Suppurativa Therapeutics market involving information such as company profiles, product picture, and specification, price, capacity, cost, production, revenue, and contact information. It presents a complete evaluation of market trends, challenges, and standardization. The research study point to define and approximate the size of the market depending upon the business profile, product type, end-user, and top geographical regions.

Brief Description of The Market:

The report provides a detailed evaluation of the global and Japan Hidradenitis Suppurativa Therapeutics market by highlighting information on different aspects which include drivers, restraints, opportunities, threats, as well as progress trends, competitive landscape analysis, and key regions’ expansion status. The report also estimates the market size, price, revenue, gross margin and market share, cost structure, and growth rate. The research report includes specific segments by region (country), by company, by type, and by the application.

NOTE: Our analysts monitoring the situation across the globe explains that the market will generate remunerative prospects for producers post COVID-19 crisis. The report aims to provide an additional illustration of the latest scenario, economic slowdown, and COVID-19 impact on the overall industry.


The Scope of This Global Market Report:

The analysts forecast the representation of this global and Japan Hidradenitis Suppurativa Therapeutics market, supply, and demand, and also that the capacity, detailed investigation. This report contains the global market statistics and the dependent market is categorized by product types and application. This report recognizes the industrial base, productivity, manufacturers, and recent trends, features, which are the key requirements in the global market to enlarge the companies and promote financial growth. The report helps to understand the future outlook and prospects for the market forecast from 2020 to 2025 time-period.

Major companies listed in the market include: AbbVie, Johnson & Johnson, Merck, AstraZeneca, GlaxoSmithKline, Pfizer, Almirall, Perrigo, Bausch Health, Sun Pharma,

By the product type, the market is primarily split into: Medications, Surgery, Other

By the end-users/application, the market report covers the following segments: Hospitals, Clinics, Other

Global market by geographical region: Americas (United States, Canada, Mexico, Brazil), APAC (China, Japan, Korea, Southeast Asia, India, Australia), Europe (Germany, France, UK, Italy, Russia), Middle East & Africa (Egypt, South Africa, Israel, Turkey, GCC Countries)


You will find the coverage of global and Japan Hidradenitis Suppurativa Therapeutics market dynamics at the country level in the respective regional segments. The report comprises competitive analysis with a focus on key players and participants of the industry covering in-depth data related to the competitive landscape, positioning, company profiles, their key strategies, and product-profiling with a focus on market growth and potential. This report improves readers’ knowledge by studying important aspects including historical, current, and projected size of the global and Japan Hidradenitis Suppurativa Therapeutics market with respect to both value (revenue) and volume (production & consumption).

It Includes An Analysis of The Following:

  • Includes sector size, market size, and growth analysis by segmentation.
  • Indicates changing share of value consumption in the various segments & sub-segments across high-potential countries
  • Provides the overview, demographic analysis, and key trends across high potential countries.
  • Provides the challenges and future outlook associated with global and Japan Hidradenitis Suppurativa Therapeutics market

Customization of the Report:
This report can be customized to meet the client’s requirements. Please connect with our sales team ([email protected]), who will ensure that you get a report that suits your needs. You can also get in touch with our executives on +1-201-465-4211 to share your research requirements.

About Us is a leading global Market Research agency providing expert research solutions, trusted by the best. We understand the importance of knowing what global consumers watch and buy, further using the same to document our distinguished research reports. has worldwide presence to facilitate real market intelligence using latest methodology, best-in-class research techniques and cost-effective measures for world’s leading research professionals and agencies. We study consumers in more than 100 countries to give you the most complete view of trends and habits worldwide. is a leading provider of Full-Service Research, Global Project Management, Market Research Operations and Online Panel Services.

Contact Us
Mark Stone
Head of Business Development
Phone: +1-201-465-4211
Email: [email protected]

Source link

Global Concentrates Market Size, Share, Value, and Competitive Landscape 2021 – The Bisouv Network

COVID-19 has had extremely limited impact on concentrates in Kazakhstan in 2020, as the category tends to be unpopular and has been declining for several years. Powder concentrates, in particular, are considered outdated soft drinks that are not popular, despite still generally being available at traditional grocery retailers. Overall, the category remains poorly presented in stores, and there is a limited number of brands and flavours. Local consumers also perceive these drinks to be artificial…


Euromonitor International’s Concentrates in Kazakhstan report offers a comprehensive guide to the size and shape of the market at a national level. It provides the latest retail sales data (2015-2019), allowing you to identify the sectors driving growth. It identifies the leading companies, the leading brands and offers strategic analysis of key factors influencing the market – be they legislative, distribution, packaging or pricing issues. Forecasts to 2024 illustrate how the market is set to change.


Product coverage: Liquid Concentrates, Powder Concentrates.

Data coverage: market sizes (historic and forecasts), company shares, brand shares and distribution data.


Why buy this report?
* Get a detailed picture of the Concentrates market;
* Pinpoint growth sectors and identify factors driving change;
* Understand the competitive environment, the market’s major players and leading brands;
* Use five-year forecasts to assess how the market is predicted to develop.


Euromonitor International has over 40 years’ experience of publishing market research reports, business reference books and online information systems. With offices in London, Chicago, Singapore, Shanghai, Vilnius, Dubai, Cape Town, Santiago, Sydney, Tokyo and Bangalore and a network of over 800 analysts worldwide, Euromonitor International has a unique capability to develop reliable information resources to help drive informed strategic planning.



Low demand for unhealthy, outdated concentrates in Kazakhstan
Plethora of small players under “others” lead
Development opportunity with health and wellness products limited
Weak performance anticipated due to continued lack of interest
Concentrates unlikely to enter the unique/fresh taste trend
Concentrates to lose shares to flavoured bottled water



[email protected]

+44 203 500 2763

+1 62 825 80070

971 0503084105

Source link

Clinical Study for Hidradenitis Suppurativa

ALLCUTIS Research, LLC in Beverly is an independent clinical research site that works with local dermatologists to offer the ability to join a clinical trial without having to travel to Boston. 

Hidradenitis Suppurativa (HS) is a chronic skin disease that causes painful bumps under the skin in areas like the underarms and groin. 

Please visit our website to learn more…

Source link

PPE-Related Skin Conditions and Patient Exposure Main Issues for Dermatologists During COVID-19

Skin conditions related to prolonged personal protective equipment (PPE) exposure and a possible increased risk for contracting COVID-19 for dermatology patients are the main issues facing dermatologists during COVID-19, according to an update published in Clinics in Dermatology

The study authors wrote that frontline healthcare workers wearing PPE such as masks, goggles, hats, and gloves for long periods have reported clinical manifestations such as erythema, papules, scaling, maceration burning, itching, and stinging. In 1 study they cited, the most commonly affected areas were the nasal bridge (83%) – due to protective goggles, not facial masks – cheeks, forehead and hands.

Prolonged goggle and mask use can lead to skin conditions including contact and pressure urticaria, contact dermatitis, and aggravation of preexisting dermatides. Prolonged use of protective hats can lead to pruritus, folliculitis, or exacerbated seborrheic dermatitis. Prolonged use of gloves, as well as exaggerated hand washing with disinfectants, can lead to macerations and erosions that can potentially cause dermatitis. Study authors reported that “two-thirds of health care workers will wash their hands over 10 times a day, but only 22% are applying skin protective cream.”

Since mucous membranes have been defined as the most common point of entry for COVID-19, dermatologic patients with a compromised epidermal barrier may be at higher risk for contracting the infection during dermatology procedures or exams, the researchers noted. They pointed out that dermatologists need to be on high alert for patients with autoimmune and chronic inflammatory disorders who are taking immunosuppressive therapy, such as patients with psoriasis, atopic dermatitis, lupus, scleroderma, and hidradenitis suppurativa.

The writers of the update recommended applying skin protective cream frequently, especially before hand washing and PPE application, to prevent contact dermatitis. They also recommended dermatology practices and departments develop infection prevention measures to protect patients from an iatrogenic exposure to COVID-19. In terms of biologic treatment, they noted it was unclear whether delaying regimens is recommended.

In order to keep dermatology practices and clinics functioning during the pandemic, the investigators suggested triaging and isolating patients who come in for treatment and may have COVID-19.

“Where possible, it may prove prudent to conduct outpatient visits with teledermatology or postpone such consultations for nonemergency patients and those with fewer skin ailments,” they added.


Darlenski R, Tsankov N. COVID-19 pandemic and the skin: what should dermatologists know? Clin Dermatol. 2020;38(6):785-787. doi:10.1016/j.clindermatol.2020.03.012

Source link

Kymera Therapeutics Announces First-in-Human Dose in Phase 1 Trial of KT-474, a First-in-Class IRAK4 Protein Degrader to Treat Immune-Inflammatory Diseases

KT-474 is the first IRAK4 degrader, and first heterobifunctional small molecule protein degrader outside of oncology, to enter clinical development

Phase 1 trial to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of orally administered KT-474 in healthy volunteers, as well as in patients with atopic dermatitis or hidradenitis suppurativa

WATERTOWN, Mass., March 02, 2021 (GLOBE NEWSWIRE) — Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced that the Company recently initiated dosing in the single ascending dose (SAD) portion of the Phase 1 clinical trial evaluating KT-474 in adult healthy volunteers and patients with atopic dermatitis or hidradenitis suppurativa. KT-474 is a potential first-in-class, highly active and selective, orally bioavailable IRAK4 degrader being developed for the treatment of toll-like receptor (TLR)/interleukin-1 receptor (IL-1R)-driven immune-inflammatory diseases, such as atopic dermatitis, hidradenitis suppurativa, rheumatoid arthritis and potentially other indications.

“We are excited to initiate dosing in the SAD portion of the Phase 1 trial of KT-474, marking the first time that a heterobifunctional small molecule degrader has ever been administered to healthy volunteers,” said Jared Gollob, MD, Chief Medical Officer of Kymera Therapeutics. “Atopic dermatitis, hidradenitis suppurativa and rheumatoid arthritis collectively impact millions of people in the U.S. alone, and we believe our novel approach of degrading IRAK4 with KT-474 offers the potential to improve outcomes over current treatment options. We look forward to our next milestone of establishing safety, on-target pharmacology, and mechanistic proof-of-concept with KT-474 in healthy volunteers later this year.”

The first-in-human Phase 1 trial is a randomized, double-blind, placebo-controlled, single and multiple ascending dose study designed to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of orally administered KT-474 in adult healthy volunteers and patients with atopic dermatitis or hidradenitis suppurativa. Additional information on this clinical trial can be found on

“KT-474 is the first heterobifunctional protein degrader candidate to advance into the clinic for immune-inflammatory conditions, representing a significant achievement for Kymera and an important milestone for the whole field of targeted protein degradation,” said Nello Mainolfi, PhD, Co-Founder, President and CEO, Kymera Therapeutics. “I am proud of the progress that our R&D organization has made to advance our first program into the clinic in only four years, and we are looking forward to the initiation of our IRAKIMiD and STAT3 Phase 1 oncology trials in 2021, setting up a transformational year for Kymera.”

About IRAK4 and KT-474
IRAK4 is a key protein involved in inflammation mediated by the activation of TLRs and IL-1Rs. Aberrant activation of these pathways is the underlying cause of multiple immune-inflammatory conditions. KT-474 is designed to block TLR/IL-1R-mediated inflammation more broadly compared to monoclonal antibodies targeting single cytokines and enable pathway inhibition that is superior to IRAK4 kinase inhibitors by abolishing both the kinase and scaffolding functions of IRAK4.

Kymera is collaborating with Sanofi on the development of degrader candidates targeting IRAK4, including KT-474 (SAR444656), outside of the oncology and immuno-oncology fields.

About Pegasus™
Pegasus™ is Kymera Therapeutics’ proprietary protein degradation platform, created by its team of experienced drug hunters to improve the effectiveness of targeted protein degradation and generate a pipeline of novel therapeutics for previously undruggable diseases. The platform consists of informatics-driven target identification, novel E3 ligases, proprietary ternary complex predictive modeling capabilities, and degradation tools.

About Kymera Therapeutics
Kymera Therapeutics is a biopharmaceutical company focused on advancing the field of targeted protein degradation, a transformative new approach to address previously intractable disease targets. Kymera’s Pegasus™ targeted protein degradation platform harnesses the body’s natural protein recycling machinery to degrade disease-causing proteins, with a focus on undrugged nodes in validated pathways currently inaccessible with conventional therapeutics. Kymera is accelerating drug discovery with an unmatched ability to target and degrade the most intractable of proteins, and advance new treatment options for patients. Kymera’s initial programs are IRAK4, IRAKIMiD, and STAT3, which each address high impact targets within the IL-1R/TLR or JAK/STAT pathways, providing the opportunity to treat a broad range of immune-inflammatory diseases, hematologic malignancies, and solid tumors. For more information, visit

Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, implied and express statements regarding its: strategy, business plans and objectives for the IRAK4, IRAKIMiD and STAT3 degrader programs; and plans and timelines for the clinical development of Kymera Therapeutics’ product candidates, including the therapeutic potential and clinical benefits thereof. The words “may,” “might,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “expect,” “estimate,” “seek,” “predict,” “future,” “project,” “potential,” “continue,” “target” and similar words or expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, risks associated with: the impact of COVID-19 on countries or regions in which we have operations or do business, as well as on the timing and anticipated results of our current preclinical studies and future clinical trials, strategy and future operations; the delay of any current preclinical studies or future clinical trials or the development of Kymera Therapeutics’ drug candidates; the risk that the results of current preclinical studies may not be predictive of future results in connection with future clinical trials; Kymera Therapeutics’ ability to successfully demonstrate the safety and efficacy of its drug candidates; the timing and outcome of the Company’s planned interactions with regulatory authorities, including the resolution of the current partial clinical hold for KT-474; and obtaining, maintaining and protecting its intellectual property. These and other risks and uncertainties are described in greater detail in the section entitled “Risk Factors” in the Quarterly Report on Form 10-Q for the period ended September 30, 2020, filed on November 5, 2020, as well as discussions of potential risks, uncertainties, and other important factors in Kymera Therapeutics’ subsequent filings with the Securities and Exchange Commission. In addition, any forward-looking statements represent Kymera Therapeutics’ views only as of today and should not be relied upon as representing its views as of any subsequent date. Kymera Therapeutics explicitly disclaims any obligation to update any forward-looking statements. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.

Investor Contact:
Paul Cox
VP, Investor Relations and Communications

Media Contact:
Lissette L. Steele
Verge Scientific Communications for Kymera Therapeutics

Source link

How to stop chafing when running – 8 ways to avoid chafing

Chafing can occur in a number of circumstances and it’s extremely common. Chafing isn’t dangerous but it is inconvenient and uncomfortable, so we’d all rather go without it. chatted to Dr Deborah Lee from Dr Fox Online Pharmacy to find out everything you need to know about chafing and how to prevent it.

What is chafing?

Chafing, sometimes called ‘chub-rub’ is when two skin surfaces rub together repeatedly.

Dr Lee explained: “If you take any form of physical exercise, you will no doubt have experienced chafing.

“As the two surfaces rub on each other, the top layer of skin cells is stripped off. While exercising, the skin becomes moist due to excess sweating.

“The skin looks inflamed and feels sore. Blisters can appear, which may burst, bleed, or in severe cases become infected.”

READ MORE-  Fatty liver disease symptoms: Eight warning signs of liver damage

How to stop chafing when running

Chafing is not a medical condition – it’s local tissue trauma that can happen to anyone.

This trauma is a real nuisance but it can also lead to a few nasty complications.

Dr Lee said: “For example, chafing under the breasts and in the groin can lead to intertrigo – a local infection with bacteria or yeasts within the skin folds.

“If you have chafing between your toes, this can lead to athlete’s foot which is a specific infection caused by fungi called dermatophytes.”

If chafing causes a blister and it bursts, this is a portal of entry for infection to the skin.

Dr Lee explained: “Rarely, serious skin infections such as cellulitis may arise from an area of chafing. Cellulitis is a medical emergency and often requires hospital admission.”

Bowel cancer symptoms: ‘Elongated’ poo could be a sign  [INFORMER]
Brazil variant symptoms: Three symptoms to spot  [INSIGHT]
Diabetes type 2 symptoms: ‘Foot drop’ is a sign of high blood sugar  [EXPLAINER]

How to stop chafing when running?

Dr Lee has revealed seven ways to prevent chafing when exercising.

Firstly, you should make sure your armpits are shaved properly so there are no hairs visible or leave the hair long. Stubble will cause chafing, so go one way or the other.

You should also use a non-irritant, antiperspirant deodorant. Dr Lee said: “Choose one which is additive-free and suitable for your skin if it is sensitive.”

Clothing can cause chafing so it is important to wear the correct sportswear.

Dr Lee said: “Wear a well-fitted sports bra and a loose top that is not too tight around the armpits and made of a synthetic fabric that is breathable to allow moisture to evaporate.“

She added: “Don’t wear cotton T-shirts, as these trap moisture.

“Wear proper running shorts which cover your thighs and always choose properly fitted footwear and running socks.”

If specific areas of your body are prone to chafing, you can target them with baby powder.

Dr Lee said: “Apply talcum powder such as baby powder to areas of potential friction, such as under your arms, the groin area and between your thighs.”

She added: “Some dermatologists prefer to use grease rather than talcum powder, so see which works best for you.

“Applying Vaseline to the areas likely to chafe before running can help. Don’t forget to apply some to your nipples!”

Chafing is more likely in heat, so you should avoid running in the hottest part of the day and keep well hydrated.

If an area starts to feel sore and you notice chafing, Dr Lee suggests cleaning with warm water and patting it dry thoroughly.

Then, apply an antibacterial cream such as Sudocrem.

She said: “If it fails to settle, see your doctor. Stop running until the area has healed. You may need to cover the area with a plaster.”

Source link

ChemoCentryx Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Highlights Nasdaq:CCXI

— The New England Journal of Medicine highlights results of ADVOCATE Phase III trial of avacopan in ANCA-associated vasculitis —

— Applications for regulatory approval of avacopan in ANCA-associated vasculitis under review in the U.S. (PDUFA goal date of July 7, 2021), the E.U. (decision expected in H2 2021) and Japan —

— Topline data from AURORA Phase II clinical trial of avacopan in Hidradenitis Suppurativa (HS) leads to Company plans for Phase III trial of avacopan in patients with most severe form of HS —

— Topline Results of ACCOLADE Phase II clinical trial of avacopan in C3 Glomerulopathy (C3G) include improved estimated Glomerular Filtration Rate (eGFR); Company plans to discuss evidence of clinical benefit with FDA —

— Novel orally administered checkpoint inhibitor CCX559 expected to enter clinical development for next generation cancer treatment in H1 2021; avacopan study initiation for Lupus Nephritis in Q3 2021 —

— $460 million in cash and investments at year end 2020 —

— Conference call today at 5:00 p.m. Eastern Time —

MOUNTAIN VIEW, Calif., March 01, 2021 (GLOBE NEWSWIRE) — ChemoCentryx, Inc., (Nasdaq: CCXI), today announced financial results for the fourth quarter and full year ended December 31, 2020 and provided an overview of recent corporate highlights.

“Inexorably our march of progress advances, drummed on by the call to improve the lives of patients enduring diseases with grossly inadequate treatments,” said Thomas J. Schall, Ph.D., President and Chief Executive Officer of ChemoCentryx. “With regulatory applications for avacopan in ANCA-associated vasculitis accepted for review on three continents, we are preparing for our first commercial launch. In my view, avacopan has the potential to transform the lives of patients suffering from debilitating and intractable diseases, as demonstrated by the results not just in ANCA-associated vasculitis but also from our clinical trials in HS and C3G. We plan to launch a Phase III trial of avacopan in patients with severe HS in 2021, and to discuss the regulatory pathway for avacopan in C3G. Meanwhile, we are on track to initiate our next cycle of clinical development in 2021, with avacopan in lupus nephritis and – breaking entirely new ground – our orally-administered small molecule checkpoint inhibitor CCX559, designed to be a next generation cancer treatment. We sense at ChemoCentryx the opportunity to transform the therapeutic landscape to the benefit of patients – and we intend to seize it.”

Key Fourth Quarter 2020 Highlights and Recent Developments

  • In February, The New England Journal of Medicine (NEJM) published the results of the Company’s Phase III ADVOCATE trial of avacopan in ANCA-associated vasculitis, in which avacopan achieved statistical superiority in sustained remission at 52 weeks over prednisone containing standard of care.
    • The article also reported additional benefits of avacopan including significantly lower risk of relapse, enhanced renal function, decreased toxicities related to glucocorticoids, and improved quality of life.
  • The avacopan article was accompanied by an editorial in the NEJM entitled “Avacopan – Time to Replace Glucocorticoids?” By Dr. Kenneth J. Warrington, Chair in the Division of Rheumatology, Department of Internal Medicine at Mayo Clinic in Rochester, Minn.
  • In February, the Company announced the appointment of Tausif “Tosh” Butt as Executive Vice President, Chief Operating Officer. Mr. Butt brings more than 20 years of executive management expertise in roles including sales and marketing with global pharmaceutical companies such as AstraZeneca, GlaxoSmithKline and Sanofi.
  • In December, the Company announced topline data from the ACCOLADE trial of avacopan for patients with the very rare disorder known as C3 Glomerulopathy (C3G). As in ANCA vasculitis, avacopan demonstrated statistically significant improvement in renal function as measured by the pre-specified endpoint of eGFR compared to placebo over 26 weeks of blinded treatment. While the change from baseline to Week 26 in C3 Glomerulopathy Histologic Index (C3G HI) Disease Activity score (primary endpoint) was improved with avacopan but not statistically different between the two treatment groups, the pre-specified secondary histology endpoint of C3G HI Disease Chronicity score (measuring progression of fibrosis) did demonstrate statistically significant benefit for avacopan over placebo. Avacopan was safe and well tolerated in C3G patients. Based on these data, ChemoCentryx plans to discuss evidence of clinical benefit for avacopan in C3G, for which there are no approved therapies, with the FDA.
  • The marketing authorization application for avacopan in the treatment of ANCA-associated vasculitis was validated by the European Medicines Agency (EMA) in November, and very recently (February) the Japanese New Drug Application was accepted for review by the Pharmaceuticals and Medical Devices Agency (PMDA).
  • In October, ChemoCentryx reported topline data from AURORA, the randomized, double-blind, placebo-controlled, multi-center Phase II clinical trial of avacopan for the treatment of Hidradenitis Suppurativa (HS) in patients with moderate or severe disease. Avacopan at 30 mg BID demonstrated a statistically significant higher response than placebo in the pre-specified Hurley Stage III (severe) HS patients and the Company plans to advance avacopan into Phase III development in this patient population.
  • The Company remains on track to initiate Phase I clinical development of its orally administered checkpoint inhibitor, CCX559, for cancer in the first half of 2021, and a clinical study of avacopan in lupus nephritis in the third quarter of 2021.
  • The Company maintained a strong balance sheet, with reported cash, cash equivalents and investments of $460.4 million at December 31, 2020.

Fourth Quarter and Full Year 2020 Financial Results

Revenue was $4.4 million for the fourth quarter of 2020, compared to $10.0 million for the same period in 2019. For the full year ended December 31, 2020, revenue was $64.9 million, compared to $36.1 million in 2019. Revenue is recognized based on actual costs incurred as a percentage of total budgeted costs as the Company completes its performance obligations under its alliance agreements. The quarterly decrease from 2019 to 2020 was primarily attributable to lower costs incurred in 2020 due to the completion of the avacopan ADVOCATE Phase III pivotal trial. The year-over-year increase was driven by the acceleration of revenue recognition associated with the CCX140 agreement with Vifor. Following the decision to discontinue development of CCX140 in focal segmental glomerulosclerosis, $46.7 million of deferred revenue was recognized as contract revenue. This increase was partially offset by lower costs incurred due to the completion of the avacopan ADVOCATE Phase III pivotal trial in 2020.

Research and development expenses were $21.2 million for the fourth quarter of 2020, compared to $19.2 million for the same period in 2019. Full year 2020 research and development expenses were $77.9 million, compared to $70.3 million in 2019. The increases from 2019 to 2020 were primarily attributable to professional fees associated with the preparation of the NDA submission for avacopan for the treatment of ANCA vasculitis and higher research and drug discovery expenses, including those tied to the advancement of CCX559, the Company’s orally administered checkpoint inhibitor. These increases were partially offset by lower expenses due to the completion of the avacopan ADVOCATE Phase III pivotal trial and the CCX140 LUMINA-1 Phase II clinical trial in 2019.

General and administrative expenses were $12.7 million for the fourth quarter of 2020, compared to $7.0 million for the same period in 2019. Full year 2020 general and administrative expenses were $42.2 million, compared to $24.2 million in 2019. The increases from 2019 to 2020 were primarily due to higher employee-related expenses, including those associated with our commercialization planning efforts, and higher professional fees.

Net loss for the fourth quarter of 2020 was $29.9 million, compared to a net loss of $15.5 million for the same period in 2019. Full year 2020 net loss was $55.4 million, compared to a net loss of $55.5 million in 2019.

Total shares outstanding at December 31, 2020 were approximately 69.5 million shares.

Cash, cash equivalents and investments totaled $460.4 million at December 31, 2020. The Company expects to utilize cash, cash equivalents and investments in the range of $145 million to $155 million in 2021.

Conference Call and Webcast

The Company will host a conference call and webcast today, March 1, 2020 at 5:00 p.m. Eastern Time / 2:00 p.m. Pacific Time. To participate by telephone, please dial (877) 303-8028 (Domestic) or (760) 536-5167 (International). The conference ID number is 8283128. A live and archived audio webcast can be accessed through the Investors section of the Company’s website at The archived webcast will remain available on the Company’s website for fourteen (14) days following the conference call.

About ChemoCentryx

ChemoCentryx is a biopharmaceutical company developing new medications for inflammatory and autoimmune diseases and cancer. ChemoCentryx targets the chemokine and chemoattractant systems to discover, develop and commercialize orally administered therapies. ChemoCentryx’s lead drug candidate, avacopan (CCX168), successfully completed a pivotal Phase III trial in ANCA-associated vasculitis and a New Drug Application is under review by the U.S. Food and Drug Administration. Avacopan is also in late stage clinical development for the treatment of severe Hidradenitis Suppurativa and C3 glomerulopathy (C3G).

ChemoCentryx also has early stage drug candidates that target chemoattractant receptors in other inflammatory and autoimmune diseases and in cancer.

Forward-Looking Statements
ChemoCentryx cautions that statements included in this press release that are not a description of historical facts are forward-looking statements. Words such as “may,” “could,” “will,” “would,” “should,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “intend,” “predict,” “seek,” “contemplate,” “potential,” “continue” or “project” or the negative of these terms or other comparable terminology are intended to identify forward-looking statements. These statements include the Company’s statements regarding the achievement of anticipated goals and milestones, whether avacopan will be approved by the FDA, EMA or PMDA for the treatment of ANCA-associated vasculitis, the timing of the FDA’s, EMA’s and PMDA’s decision on the NDA, MAA, and JNDA, respectively, whether avacopan will be an effective treatment in other indications such severe HS and C3G, whether a Phase III trial of avacopan in patients with severe HS will commence in 2021, whether avacopan for lupus nephritis and CCX559 will enter clinical trials in 2021, whether actual cash utilization will fall within projections and whether the Company’s drug candidates will be shown to be effective in ongoing or future clinical trials. The inclusion of forward-looking statements should not be regarded as a representation by ChemoCentryx that any of its plans will be achieved. Actual results may differ from those set forth in this release due to the risks and uncertainties inherent in the ChemoCentryx business and other risks described in the Company’s filings with the Securities and Exchange Commission (“SEC”). Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and ChemoCentryx undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof. Further information regarding these and other risks is included under the heading “Risk Factors” in ChemoCentryx’s periodic reports filed with the SEC, including ChemoCentryx’s Annual Report on Form 10-K filed with the SEC on March 1, 2021 and its other reports which are available from the SEC’s website ( and on ChemoCentryx’s website ( under the heading “Investors.” All forward-looking statements are qualified in their entirety by this cautionary statement. This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995.

Susan M. Kanaya
Executive Vice President,
Chief Financial and Administrative Officer

Stephanie Tomei

Burns McClellan
Lee Roth

ChemoCentryx, Inc.
Condensed Consolidated Financial Statements Data
(in thousands, except per share data)
    Three Months Ended   Twelve Months Ended
    December 31,   December 31,
      2020       2019       2020       2019  
Condensed Consolidated Statements of Operations Data:                
Collaboration and license revenue from related party   $ 4,227     $ 9,871     $ 64,392     $ 35,952  
Grant revenue     131       176       499       176  
Total revenue     4,358       10,047       64,891       36,128  
Operating expenses:                
Research and development     21,227       19,202       77,882       70,276  
General and administrative     12,712       6,968       42,186       24,155  
Total operating expenses     33,939       26,170       120,068       94,431  
Loss from operations     (29,581 )     (16,123 )     (55,177 )     (58,303 )
Other income (expense), net     (295 )     595       (179 )     2,814  
Net loss   $ (29,876 )   $ (15,528 )   $ (55,356 )   $ (55,489 )
Basic and diluted net loss per common share   $ (0.43 )   $ (0.26 )   $ (0.84 )   $ (0.98 )
Shares used to compute basic and diluted net loss per common share   69,253       58,938       65,688       56,898  
            December 31,
              2020       2019  
Condensed Consolidated Balance Sheets Data:                
Cash, cash equivalents and investments           $ 460,370     $ 202,240  
Working capital             390,012       115,282  
Total assets             518,899       209,083  
Long-term debt, net             24,401       19,786  
Accumulated deficit             (485,342 )     (429,986 )
Total stockholders’ equity             385,613       66,000  


Source link